Cernitol™ Treatment of Chronic Alcoholics
M. Veron, Director of the National Rehabilitation Institute at
Saint-Maurice, France
Summary
A Clinical and Laboratory Study of Cernitol™ in Malnourished Chronic Alcoholics
In a double blind test, 44 patients being treated for chronic alcoholism were divided into
two random groups and given Cernitol™, a pollen preparation, or placebos, respectively.
The study revealed considerable differences between the groups for the following
variables and in favour of the group undergoing treatment: overall result according to the
doctor, body weight, appetite, asthenia, psychomotor capacity and memory.
The laboratory tests size showed significant differences in protein, total lipids and
cholesterol in serum and in I 7-OH-steroids and 17-oxi-steroids in the urine. All values
were higher in tire group undergoing treatment. ATO side effects were noted.
Earlier experiments have shown that Cernitol™ produces good results in patients
suffering from nutrition problems in the form of emaciation, loss of appetite and physical
and mental asthenia (1, 2). These effects have been noted both in children and elderly
patients convalescing after various illnesses. In particular, protein synthesis increased
as did secretion of 17-OH-steroids and 17-oxi-steroids. No side effects were shown as
being attributable to the preparation, and significant results were achieved after as little
as two months of treatment.
At the National Rehabilitation Institute in Saint-Maurice, a large number of chronic
alcoholics are cared for in abstinence. Low body weight, expressed loss of appetite,
physical and mental asthenia, and poor general condition are characteristics common to
all of them.
In view of the good results previously obtained by giving Cernitol™ to patients in this
type of condition, a double blind test of Cernitol™ was carried out.
Material and Methods
44 male in-patients undergoing cures for chronic alcoholism were divided into two
random groups and given Cernitol™ or placebos over a period of six weeks. The dose
administered was four tablets a day, each tablet containing 120 mg Cernitin™ extract
T60™ and 6 mg Cernitin™ GBX™ respectively. The age, weight etc of patients in both
groups was as set out in Table 1.
Table 1
| |
Average Age |
Average Weight |
Poly-Neuritics |
Cirrhotic |
| Group Treated |
55 |
53.7 |
18 |
3 |
| Controls |
53 |
53.0 |
20 |
1 |
The following examinations were carried out before and after the treatment. Treatment
did not start until after the patients had been admitted to the Institute for one week.
Body Weight
Muscle power was recorded according to Bidoux method (3), three groups of muscles in
the ankle joint and hand being tested.
Memory and attentiveness were tested using the method outlined by Couve & Lezine
(3), partly in the form of a classification test, and partly in the form of an exclusion test
using certain letters and digits.
An overall assessment was made by the doctor, on a scale of much improved,
somewhat improved, and unchanged.
The following serum values were ascertained by laboratory tests: protein, total lipids,
cholesterol, pyruvate, sodium, potassium chloride and urea. 17-OH-steroids and
17-oxi-steroids in the urine were determined over a period of 24 hours.
Statistical calculations were made using Student's "t" Test.
Results
The doctor's overall assessment of the results showed that the condition of 68% of the
group undergoing treatment was much improved, while the condition of the controls
remained unchanged (p < 0.001). Please see Table 2.
Table 2
| |
Much Improved |
Somewhat Improved |
Unchanged |
| Group Treated |
|
|
|
| Controls |
0 |
3 |
19 |
The average body weight of patients undergoing treatment increased by 3.6 kg, whereas
that of controls decreased by 0.6kg (p 0.001).
The appetites of all patients undergoing treatment improved or returned to normal, but
not the appetites of any of the controls (p < 0.001).
Levels of fatigue were reduced in 54% of the group being treated, but were not reduced
in any of the controls (p < 0.001).
Muscle power was more than tripled (an increase of 305%) in members of the group
being treated, and was increased by 17% among controls (p < 0.001).
The classification test revealed an improvement of 81 points among members of the
group being treated, but a deterioration of 5 points among controls (p < 0.00~).
The memory test showed an improvement of 59% among members of the group being
treated, but a deterioration of 9% among controls (p < 0.001).
The blood tests carried out revealed increases in protein, lipids and cholesterol in the
group being treated in relation to the controls (p < 0.001). Other values showed no
significant changes. Urine tests showed increases in 17-OH-steroids and 17-oxi-steroids
in samples from the group being treated, but no such increases in the samples from the
controls (p < 0.001) (please see Table 3). There were no significant differences in the
creatinine, urea, sodium or potassium content of the urine samples from either group.
No side effects of the preparation were noted.
Table 3
| |
Serum
Protein |
Serum
Lipids |
Serum
Cholesterol |
U-17-OH- steroids mg per 24 hours |
U- 17-oxi- Steroids mg per 24 hours |
| Group Treated: |
|
|
|
|
|
| Before |
64.3 |
7.13 |
2.00 |
2.60 |
6.00 |
| After |
71.5 |
8.43 |
2.71 |
4.63 |
7.23 |
| Controls: |
|
|
|
|
|
| Before |
67.3 |
7.40 |
2.00 |
3.04 |
5.00 |
| After |
65.5 |
7.22 |
2.00 |
2.99 |
4.80 |
Conclusions
Previous research carried out in Poland (4) showed that, in an experiment with rats,
Cernitol™ almost completely eliminated the injury conducted to the liver caused by
liberal access to alcohol over a period of three months.
The present experiment showed that existing alcoholic injury can be treated and good
results obtained during a period of rehabilitation and abstinence. Results related in
particular to improved anabolism of fat and protein in the form of better appetite,
increased muscle power and increased body weight. These can be assumed to result
inter alia from improved function of the liver as the result of the administration of
Cernitol™. In addition, there was a perceptible improvement in patients' mental state
and asthenia. For this reason Cernitol™ appears to be well suited to deal with the shifts
in the metabolism which occurs in cases of chronic alcoholism among human beings.
References
- A new natural treatment for protein malnutrition states. Results of a double-blind
clinical trial Dubassy, J.. Gazette Medical de France (1972), 79:7674-83
- A new appetite stimulant drug based on pollen extracts with no hormonal or
antihistamine action, in pediatric practice. Report of 100 cases.- Leparcq, G: La
vie Medicale (1973), 54:1352-2
- Clinical and laboratory study of a new appetite stimulant treatment in
malnourished chronic alcoholics. Veron. M: L 'Hospital information Therapeutique
(France) (1973), 3.. No.10
- Cemitol vid kronisk alkoholforgftning av rattor.Wojcicki J et al: Swed J Biol Med
(1989), 2.'13-14